Comparative Pharmacology
Head-to-head clinical analysis: HETLIOZ LQ versus RAMELTEON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETLIOZ LQ versus RAMELTEON.
HETLIOZ LQ vs RAMELTEON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melatonin receptor agonist; selectively binds to and activates MT1 and MT2 receptors in the suprachiasmatic nucleus, regulating circadian rhythms and promoting sleep.
Selective melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus; promotes sleep by mimicking the effects of endogenous melatonin.
20 mg orally once daily at bedtime, taken within 30 minutes of bedtime with or without food. For delayed sleep-wake phase disorder: 0.5 mg/kg (up to 20 mg) once daily at bedtime.
8 mg orally once daily within 30 minutes of bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.0 hours; clinical context: dosing at bedtime aligns with short half-life to avoid residual daytime sedation.
Clinical Note
moderateRamelteon + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Ramelteon."
Clinical Note
moderateRamelteon + Sulfisoxazole
"The serum concentration of Sulfisoxazole can be increased when it is combined with Ramelteon."
Clinical Note
moderateRamelteon + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Ramelteon."
Clinical Note
moderateRamelteon + Cyclosporine
1-2.6 hours. The terminal half-life is short (mean ~1.3 hours) with no accumulation upon repeated dosing. Clinical context: Rapid clearance supports once-nightly dosing for sleep onset insomnia.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites; unchanged tasimelteon in urine <1%; fecal excretion accounts for approximately 80% of total clearance.
Ramelteon is extensively metabolized, primarily via CYP1A2 and to a lesser extent CYP2C9 and CYP3A4. Approximately 84% of the dose is excreted in urine as metabolites, with 4% as unchanged drug. Fecal excretion accounts for about 4% of the dose.
Category C
Category C
Melatonin Receptor Agonist
Melatonin Receptor Agonist
"The metabolism of Cyclosporine can be decreased when combined with Ramelteon."